| Accession Number: | 0001127602-21-025686 |
| Date: | 2021-09-20 |
| Issuer: | BIOCRYST PHARMACEUTICALS INC (BCRX) |
| Original Submission Date: |
MCKEE AMY E
4505 EMPEROR BLVD.
SUITE 200
DURHAM, NC 27703
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NON-QUALIFIED STOCK OPTION | 15.02 | 2021-09-20 | deemed execution date | A | 53,333 (a) | 2031-09-20 | common stock 53,333 | $15.02 | 53,333 | direct |
| ID | footnote |
|---|---|
| f1 | automatic non-employee director grant pursuant to the biocryst pharmaceuticals, inc. amended and restated stock incentive plan. |
| f2 | the option vests 1/36 per month for a period of 36 months, beginning on october 20, 2021 |
